Board approves amalgamation of two wholly owned subsidiaries

Scheme filed with the NCLTStrategic Transactions View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.5%Reaction day

₹2212.60

prior close

₹2312.20

announcement price

In-mkt

timing

Nifty Midcap 150market+1.1%+3.4% vs market

Pharmaceuticals peers, median of 174sector+1.2%+3.3% vs sector

On the reaction day the stock moved 3.4 pts more than Nifty Midcap 150 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.0

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.5+1.1+3.4+1.2+3.3

Next day

+13.1+2.0+11.1+3.1+10.0

+12.5+2.3+10.2+4.7+7.8

+11.6+3.2+8.4+4.7+6.9

+12.7+2.2+10.5+3.2+9.4

+12.1+3.5+8.7+3.2+9.0

+14.8+6.2+8.6+4.9+9.9

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board approved merging Prolijune Lifesciences and Pavi Buildwell into Mankind Pharma, with an appointed date of April 1, 2027, subject to shareholder, creditor and NCLT approval. It also noted a proposed merger of Upakarma Ayurveda into Mankind Consumer Products. Standalone quarter revenue was Rs 3,145.22 crore and profit Rs 581.95 crore, while consolidated revenue was Rs 4,337.86 crore and profit Rs 716.12 crore, with EPS of Rs 17.23.

Likely market impact

Consolidating wholly owned units should simplify the group structure without any cash payout. Strong quarterly profit supports sentiment, but the schemes still need approvals.